Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03429101 | A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | terminated | Phase 1 | 6 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2021 | clinicaltrials |
| NCT03292536 | Merestinib on Bone Metastases in Subjects With Breast Cancer | terminated | Phase 1 | 2 | University of UtahOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT01495247 |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer |
| terminated |
| Phase 1 / Phase 2 |
| 18 |
| Novartis PharmaceuticalsINDUSTRY |
| 2 |
| Dec 8, 2020 |
| clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | terminated | Phase 1 | 2 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT00075673 | Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer | terminated | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00905021 | Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer(EXTENT) | terminated | Phase 1 / Phase 2 | 4 | Baylor Breast Care CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT00003086 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT00090480 | Vaccine Treatment for Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01532960 | Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer(Breast 41) | terminated | Phase 1 | 11 | Craig L Slingluff, JrOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00616122 | Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | University of California, San FranciscoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT00531271 | ABI-008 Trial in Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 85 | CelgeneINDUSTRY | 1 | Nov 14, 2019 | clinicaltrials |
| NCT01118975 | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | terminated | Phase 1 / Phase 2 | 12 | University of Maryland, BaltimoreOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02582801 | Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer | terminated | Phase 1 | 46 | Jiang WuOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT00972023 | DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer | terminated | Phase 1 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03062007 | Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab | terminated | Phase 1 | 6 | Biointegrator LLCINDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT02136927 | Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer | terminated | Phase 1 | 33 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 60 | PfizerINDUSTRY | 1 | Apr 29, 2019 | clinicaltrials |
| NCT02384746 | Phase I Study of the Combination of MLN9708 and Fulvestrant(Millennium) | terminated | Phase 1 | 9 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT02658084 | Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 2 | University of MiamiOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02129205 | A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 40 | PfizerINDUSTRY | 1 | Mar 29, 2019 | clinicaltrials |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02067884 | Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery | terminated | Phase 1 | 34 | University of Southern CaliforniaOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03316794 | A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | terminated | Phase 1 | 2 | AbbVieINDUSTRY | 1 | Dec 17, 2018 | clinicaltrials |
| NCT00584012 | A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer | terminated | Phase 1 | 9 | Susan L RoederOTHER | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02297230 | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | terminated | Phase 1 / Phase 2 | 44 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT01051401 | Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer | terminated | Phase 1 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | terminated | Phase 1 / Phase 2 | 81 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00827580 | Eniluracil Hand Foot Syndrome | terminated | Phase 1 | 3 | West Virginia UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02524951 | Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer | terminated | Phase 1 | 5 | Northwell HealthOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer(STEFNE) | terminated | Phase 1 / Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT02708511 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | terminated | Phase 1 | 2 | Sanjiv Sam GambhirOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT00004261 | EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | terminated | Phase 1 | — | University Health Network, TorontoOTHER | 1 | Feb 22, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jan 15, 2021source: clinicaltrials